Accelero Bioanalytics GmbH proudly announced today that the company has received full authorization from Berlin´s local LAGeSo authority for the bioanalytical processing of genetically modified organisms (GMO). The notification allows for the operation of safety level S2 laboratories (registration No. 661/12) according to the German genetic engineering safety regulations (Gentechniksicherheitsverordnung, GenTSV).

Accelero Bioanalytics GmbH is proud to announce that the company has joined the German Association of Biotechnology Industry (BIO Deutschland e.V.) as a full member.

The product is the process - is it? Quality aspects in the production of advanced therapeutic medical products (ATMP).

The Paul-Ehrlich-Institute as the responsible German authority organizes a meeting in cooperation with BIOTOP on the development and production of cell-based therapeutics. The event will be a forum for public institutions, R&D companies and medical advisors from pharma and biotech to discuss open topics in the field of GMP production as well as regulatory issues.

Accelerō Bioanalytics GmbH, a GLP bioanalytical ligand binding assay service provider establishing an innovative business and marketing paradigm, announced today that it has entered into a collaboration agreement with LPT Laboratory of Pharmacology and Toxicology GmbH & Co KG (Hamburg, Germany).

Accelero® Bioanalytics GmbH, a Berlin-based biotech contract research business focusing on the emerging field of bioanalytical ligand binding DMPK assay services, announced today that Applied Biosystems´ ViiA™ 7 Dx Real-Time RT-qPCR System was added to its instrumentation.

The ViiA™ 7 Dx qPCR system is a new generation real time PCR system equipped with a 384-well interchangeable thermal cycling block for high throughput low volume sample analysis in real time.